Grail, Inc.

Background

Company Name	Grail, Inc.
Stock Symbol	GRAL
Class Period	May 13, 2025 to February 19, 2026
Lead Plaintiff Motion Deadline	August 04, 2026

Submit Your Information

If you suffered a loss on your Grail, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filling out this form mean you have joined any lawsuit.

First Name*

Middle Initial

Last Name*

Email*

Phone*

If representing a Corporation, Trust, Partnership or other entity, Name of Entity

If representing an Entity, Position at Entity

Mailing Address

City

State/Province

ZIP/Postal Code

Country

Are you a current or former employee of the company?

Did you purchase any shares before May 13, 2025?

Shares Purchased

Number of Shares	Buy Date	Price Per Share	Add
Purchased quantity	Purchased month Purchased day Purchased year

Shares Sold

Number of Shares	Sell Date	Price Per Share	Add
	Sold month Sold day Sold year

Additional Comments

Background

On February 19, 2026, Grail announced that the “primary endpoint of statistically significant Stage III-IV [cancer] reduction was not observed” in its NHS-Galleri Trial due, in part, to “probably need[ing] a longer follow-up time to be able to [compare the study arms] adequately.”

On this news, Grail’s stock price fell $51.32, or 50.5%, to close at $50.21 per share on February 20, 2026, thereby inuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the confidence management provided in light of the “Positive Top-Line Results” from the trial’s first screening round and the Pathfinder studies was misplaced and ignored potential trendlines in unreleased topline data and other information learned since the inception of the study that suggested three years would be less sufficient than previously thought to demonstrate the achievability of the primary endpoint; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Submit Your Information